Abbott Secures Exclusive U.S. Rights for SimpleScreen Colorectal Cancer Test

Key Facts

In a strategic move to bolster its leadership in the medical diagnostics sector, Abbott Laboratories has secured exclusive U.S. commercialization rights for Freenome's SimpleScreen test. This FDA-approved, blood-based screening is designed for colorectal cancer detection in adults at average risk. The partnership allows Abbott to expand its diagnostic reach into the growing cancer screening market without overlapping its existing testing platforms.

According to reports, Abbott aims to capture growth in blood-based diagnostics, a field gaining significant traction among clinicians and patients. This expansion comes as the company balances new MedTech investments against margin pressures noted in recent financial performance. Per market data, the inclusion of SimpleScreen provides Abbott with a fresh growth angle alongside other screening options currently available in the U.S. market.

Abbott (ABT) shares stood at $107.27 at close on July 28, 2026, having traded between a day high of $109.26 and a low of $105.97. Investors will be watching for physician uptake and payer support for SimpleScreen as primary catalysts for future revenue. On the macroeconomic front, the market is looking toward the U.S. Initial Jobless Claims data on July 23, 2026, for broader sentiment cues.